In overall, our results uncovered a new pathogenic role of Runx1 in MMT development, representing a novel druggable target for the development of targeted therapy against the MMT‐driven formation of tumor‐promoting CAFs in clinical NSCLC. This evidence concerns the gene RUNX1 and neoplasm.